Skip to main content

Table 3 Univariate association analysis of survival

From: Milan criteria in the MELD era—is it justifiable to extend the limits for orthotopic liver transplantation?

  Non-survivor, N = 53 Survivor, N = 67 p overall
Age 65 0.248
 < 65 37 (69.8%) 54 (80.6%)
 > 65 16 (30.2%) 13 (19.4%)
Sex 1.000
 F 10 (18.9%) 12 (17.9%)
 M 43 (81.1%) 55 (82.1%)
AFP (ng/ml) 36.1 [5.40; 234] 6.20 [3.50; 26.5] < 0.001
Waiting_time (days) 236 [77.0; 370] 198 [64.5; 316] 0.319
D (mm) 36.8 (20.1) 30.3 (21.1) 0.091
MELD 0.703
 MELD ≤ 15 29 (69.0%) 42 (76.4%)
 MELD = 15–30 9 (21.4%) 8 (14.5%)
 MELD > 30 4 (9.52%) 5 (9.09%)
preTreat 0.319
 No pre-treatment 23 (43.4%) 22 (32.8%)
 Pre-treatment 30 (56.6%) 45 (67.2%)
N 0.109
N = 1 18 (48.6%) 41 (65.1%)
N = 1–3 12 (32.4%) 18 (28.6%)
N > 3 7 (18.9%) 4 (6.35%)
Grade 0.559
 1 8 (32.0%) 15 (44.1%)
 2 15 (60.0%) 18 (52.9%)
 3 2 (8.00%) 1 (2.94%)
Asan < 0.001
 Exceeding 25 (47.2%) 10 (14.9%)
 Fulfilling 28 (52.8%) 57 (85.1%)
AFP score 0.002
 > 2 18 (40.9%) 8 (13.1%)
 ≤ 2 26 (59.1%) 53 (86.9%)
MC 0.001
 Exceeding 30 (56.6%) 16 (23.9%)
 Fulfilling 23 (43.4%) 51 (76.1%)
UTS < 0.001
 Exceeding 26 (49.1%) 8 (11.9%)
 Fulfilling 27 (50.9%) 59 (88.1%)
  1. Data are shown as the average and standard deviation (round brackets) for normally distributed data and as the median and quantiles (square brackets) for non-normally distributed data
  2. AFP alpha-feto protein in ng/ml, D diameter of the largest tumor in mm, MELD model of end-stage liver disease, N number of tumors, MC Milan criteria, UTS up-to-seven criteria